NEW YORK, May 1 – Protein structure determination company Signature BioScience said Tuesday it had appointed David Spellmeyer chief scientific officer and vice president of drug discovery.

Spellmeyer will be in charge of developing Signature BioScience’s new drug discovery efforts and validating the company’s technology.

Previously Spellmeyer was executive director at DuPont Pharmaceuticals Research Laboratories, where he oversaw the computational chemistry aspects of drug discovery and information technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.